JAP10 Rec'd PCT/PTO 20 DEC 2005

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731064124 US Express Mail Label Number

20. 

Other items or information: unexecuted Declaration and Application Data Sheet

...>

20 December 2005

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) DV/4-33628A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 30 June 2003 (30.06.03) PCT/EP04/007047 29 June 2004 (29.06.04) TITLE OF INVENTION SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS APPLICANT(S) FOR DO/EO/US **BOUGUELERET ET AL** Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 3. 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. a. 
is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. A have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). 10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

U.S. APPLICATION NO					DV/4-3362	DOCKET NUMBER					
The following fe										ULATIO	NS PTO USE
The following for	00 0.0 0.								ONLY		
21. 🛛 Basi	c nationa	al fee						\$300			
22. Examination Fee											
If International preliminary examination report was prepared by USPTO											
and all claims satisfy provisions of PCT Article 33(1)-(4)											
23. Search fee											
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$  ☑ If International Search Report was prepared and provided to the Office \$400											
All other situations. \$											
TOTAL OF 21, 22 AND 23 =										900	
Additional fee fo	r specific	cation and di		n paper over 100 s	heets (e	xcludin	ia seau	ence listing	or comp	uter	
program listing f	iled in a	n electronic r	medium). The	e fee is \$250 for ea	ch additi	onal 50	) sheet	s of paper o	r fraction	1	
Total Sheets	Extra	sheets		ach additional 50 or d up to a whole nu			R/	ATE			
100 - 100 =	18	/50 =	thereof (round	0		X	\$	250	\$		
				C. Introduce				-			
Surcharge of \$1					□ 30				\$		
months from the earliest claimed priority date (37 CFR 1.492(e)).  CLAIMS NUMBER FILED NUMBER EXTRA RATE											
Total claims			- 20 =			X	\$	50_	\$		
Independent cla		T CLAIM(S)	-3 =			<u>X</u>	<u>\$</u> \$	200 360	\$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =									\$	900	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be									_		
filed (Note 37 CFR 1.9, 1.27, 1.28).									\$ \$	900	
SUBTOTAL =  Processing fee of \$130 for furnishing the English translation later than  30 months from the									<del>  •</del>	900	
earliest claimed priority date (37 CFR 1.492(f)).									\$		
TOTAL NATIONAL FEE =									\$	900	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied									_		
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +  TOTAL FEES ENCLOSED =									\$	900	
TOTAL TELS ENGLOSED =										ount to	\$
										funded	Ψ
									C	harged	\$
a. 🔲 A chec	k in the a	amount of \$_		to cover the ab	ove fees	is end	losed.	'			
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.											
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with											
Customer No. 001095, which is currently:											
					/ /	T. Prin				•	<del></del>
Novartis  Attórney for Applicants Corporate Intellectual Property  Attórney for Applicants Reg. No. 43,019											
Corporate Intellectual Property One Health Plaza, Building 104  Ceg. No. 43,019 (617) 871-3346											
East Hanover, NJ 07936-1080 Date: December 20, 2005											
Date:	)ecen	ulver H	0.4005								